The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Open accessAbstract
BACKGROUND: The inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) is a potential synthetic lethal therapeutic strategy for the treatment of cancers with specific DNA-repair defects, including those arising in carriers of a BRCA1 or BRCA2 mutation. We conducted a clinical evaluation in humans of olaparib (AZD2281), a novel, potent, orally active PARP inhibitor. METHODS: This was a phase 1 trial that included the analysis of pharmacokinetic and pharmacodynamic characteristics of olaparib. Selection was aimed at having a study population enriched in carriers of a BRCA1 or BRCA2 mutation. RESULTS: We enrolled and treated 60 patients; 22 were carriers of a BRCA1 or BRCA2 mutation and 1 had a strong family history of BRCA-associated cancer but declined to undergo mutational testing. The olaparib dose and schedule were increased from 10 mg daily for 2 of every 3 weeks to 600 mg twice daily continuously. Reversible dose-limiting toxicity was seen in one of eight patients receiving 400 mg twice daily (grade 3 mood alteration and fatigue) and two of five patients receiving 600 mg twice daily (grade 4 thrombocytopenia and grade 3 somnolence). This led us to enroll another cohort, consisting only of carriers of a BRCA1 or BRCA2 mutation, to receive olaparib at a dose of 200 mg twice daily. Other adverse effects included mild gastrointestinal symptoms. There was no obvious increase in adverse effects seen in the mutation carriers. Pharmacokinetic data indicated rapid absorption and elimination; pharmacodynamic studies confirmed PARP inhibition in surrogate samples (of peripheral-blood mononuclear cells and plucked eyebrow-hair follicles) and tumor tissue. Objective antitumor activity was reported only in mutation carriers, all of whom had ovarian, breast, or prostate cancer and had received multiple treatment regimens. CONCLUSIONS: Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer associated with the BRCA1 or BRCA2 mutation. (ClinicalTrials.gov number, NCT00516373.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, BRCA-mutated cancer cells are selectively sensitive to agents that require repair of double-strand breaks by homologous recombination, such as PARP1 inhibitors [5–7].”
From Hereditary Breast Cancer and the BRCA1-Associated FANCJ/BACH1/BRIP1 (2011) · cites this paper as [7]
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Self-citationInstability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N. C., Tutt, A. N. J., & Ashworth, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1457 · Cited by 1,690
Self-citationAmé, J., Spenlehauer, C., & de MURCIA, G. (2004) · BioEssays · doi:10.1002/bies.20085 · Cited by 1,463
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1691 · Cited by 1,405
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O’Connor, M. J., Tutt, A. N. J., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,311
Self-citationSecondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
Research works printed but not linked: 1
- 10.1042/BST0290655 · DOI
Cited by
Sorted by citations
Items 1,001–1,012 of 1,012
Ivy, S. P., Liu, J. F., Lee, J., Matulonis, U. A., & Kohn, E. C. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1156857 · Cited by 60
Yang, B., Li, X., Fu, Y., Guo, E., Ye, Y., Li, F., Liu, S., Xiao, R., Liu, C., Lu, F., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2370 · Cited by 55
Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
Lim, J., & Tan, D. S. P. (2017) · Cancers · doi:10.3390/cancers9080109 · Cited by 52
BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer
Pothuri, B. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt307 · Cited by 50
Boudreau, A., van't Veer, L. J., & Bissell, M. J. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.20880 · Cited by 43
Efforts to Develop KRAS Inhibitors
Holderfield, M. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031864 · Cited by 43
Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy
Huang, J.-L., Chang, Y.-T., Hong, Z.-Y., & Lin, C.-S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063238 · Cited by 42
Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders
Schadt, E. E., Buchanan, S., Brennand, K. J., & Merchant, K. M. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00252 · Cited by 39
The combination of olaparib and camptothecin for effective radiosensitization
Miura, K., Sakata, K.-I., Someya, M., Matsumoto, Y., Matsumoto, H., Takahashi, A., & Hareyama, M. (2012) · Radiation Oncology · doi:10.1186/1748-717x-7-62 · Cited by 33
Szabova, L., Bupp, S., Kamal, M., Householder, D. B., Hernandez, L., Schlomer, J. J., Baran, M. L., Yi, M., Stephens, R. M., Annunziata, C. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095649 · Cited by 25
Comprehensive analysis of DNA damage repair deficiency in 10,284 pan–cancer study
Xiao, Y., Lu, D., Lei, M., Xie, W., Chen, Y., Zheng, Y., Wang, C., Zhao, J., Zhu, Z., Zhao, X., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-5449 · Cited by 22
Lips, E. H., Debipersad, R. D., Scheerman, C. E., Mulder, L., Sonke, G. S., van der Kolk, L. E., Wesseling, J., Hogervorst, F. B. L., & Nederlof, P. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0198 · Cited by 22
Metadata
- Authors
- Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., Ashworth, A., Carmichael, J., Kaye, S. B., Schellens, J. H. M., & de Bono, J. S.
- Affiliations
- National Health Service (GB)
- The Netherlands Cancer Institute (NL)
- Institute of Cancer Research (GB)
- AstraZeneca (United Kingdom) (GB)
- Utrecht University (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-07-09
- Volume
- 361
- Issue
- 2
- Pages
- 123-134
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2171972386
- Cited by
- 3,634
- References
- 30
- Citations by year
- 2026: 79 · 2025: 113 · 2024: 126 · 2023: 152 · 2022: 188 · 2021: 189 · 2020: 173 · 2019: 195 · 2018: 190 · 2017: 214 · 2016: 249 · 2015: 252 · 2014: 244 · 2013: 247 · 2012: 285
- FWCI
- 170.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- AstraZeneca
- Royal Marsden NHS Foundation Trust
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- Cancer Research UK (A8363)
- National Institute for Health and Care Research
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- olaparib, PARP inhibitors, BRCA1 mutation carriers, BRCA2 mutation carriers, synthetic lethality, DNA repair deficiency, ovarian cancer, breast cancer, prostate cancer, pharmacokinetics, pharmacodynamics, dose-limiting toxicity, thrombocytopenia, anticancer activity
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Adult, Aged, Aged, 80 and over, Dose-Response Relationship, Drug, Female, Heterozygote, Humans, Male, Middle Aged, Neoplasms, Phthalazines, Piperazines, Drug Design, Germ-Line Mutation, Genes, BRCA1, Genes, BRCA2, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
